윤미란 (연세대학교 의과대학 의생명과학부)님 | 한빛사연구자 > 한빛사

연세대학교 의과대학 의생명과학부

최종업데이트 2025.01.31.

The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC
- Cell Rep. Med., January 27, 2025 | https://doi.org/10.1016/j.xcrm.2025.101929
- 2025-01
- 한빛사논문
Discovery of a novel potent EGFR inhibitor against EGFR activating mutations and on-target resistance in NSCLC
- Clin. Cancer Res., Feb 08 2024, | https://doi.org/10.1158/1078-0432.CCR-23-2951
- 2024-02
- 의약학
- 한빛사논문
Preclinical study of a biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC
- Clin. Cancer Res., NOVEMBER 17 2022 | https://doi.org/10.1158/1078-0432.CCR-22-2180
- 2022-11
- 의약학
- 한빛사논문
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
- EMBO Mol. Med., 21 October 2019, e10581 | https://doi.org/10.15252/emmm.201910581
- 2019-10
- 의약학
- 한빛사논문

연구자 ID

저자논문